<DOC>
	<DOC>NCT00412893</DOC>
	<brief_summary>The purpose of this study is to compare the efficacy and safety of isavuconazole versus voriconazole in the treatment of patients with invasive aspergillosis.</brief_summary>
	<brief_title>Isavuconazole (BAL8557) for Primary Treatment of Invasive Aspergillosis</brief_title>
	<detailed_description>Acute invasive fungal infections caused by aspergillus, zygomycetes and other filamentous fungi remain life threatening diseases. Early treatment with highly effective anti-fungals reduces mortality. This study investigates the efficacy and safety of isavuconazole in the treatment of invasive fungal diseases, caused by Aspergillus or other filamentous fungi.</detailed_description>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Aspergillosis</mesh_term>
	<mesh_term>Voriconazole</mesh_term>
	<criteria>Patients must have proven, probable or possible invasive fungal disease caused by Aspergillus species or other filamentous fungi Female patients must be nonlactating and at no risk for pregnancy Patients with invasive fungal infections other than Aspergillus species or other filamentous fungi Evidence of hepatic dysfunction at Baseline or moderate to severe renal dysfunction Patients with chronic aspergillosis, or aspergilloma or allergic bronchopulmonary aspergillosis Patients who have received more than 4 days of systemic antifungal therapy other than fluconazole within the 7 days prior to the first administration of study medication Patients previously enrolled in a Phase III study with isavuconazole Patients with a body weight &lt;/= 40 kg</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Phase III</keyword>
	<keyword>Invasive fungal disease</keyword>
	<keyword>Aspergillus species</keyword>
	<keyword>Filamentous fungi</keyword>
	<keyword>ASP9766</keyword>
	<keyword>BAL8557</keyword>
	<keyword>Isavuconazole</keyword>
</DOC>